News: The Ugandan health ministry has launched a national vaccination programme against cervical cancer with US drug giant Merck & Co's human papillomavirus quadrivalent recombinant vaccine Gardasil. The first phase of the two-year programme will vaccinate eligible girls within age range 9 to 13 years in 12 districts, including Isingiro, Mityana, Rukungiri, Nebbi, Oyam, Ntungama and Lira. The vaccination exercise, which is supported by Merck's subsidiary Merck Sharp & Dohme, will deliver 460,000 doses of Gardasil, sufficient to vaccinate approximately 140,000 eligible girls.
BMI View: BMI 's Burden of Disease Database estimates that the number of disability-adjusted life years (DALYs) lost to cervical cancer in Uganda was 20,880 in 2010. We forecast that this will increase by 19.56% to 24,966 DALYs by 2015 and by 75.30% to 43,765 DALYs by 2030.